medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»medalphabet-266Research ArticleСтатьиОпыт применения эрибулина у пациенток с метастатическим раком молочной железы в реальной клинической практикеExperience with use of eribulin in patients with metastatic breast cancer in actual clinical practiceМанихасА. Г.ManikhasA. G.noemail@neicon.ruРаевскаяН. А.ManikhasG. M.noemail@neicon.ruМанихасГ. М.RaevskayaN. A.noemail@neicon.ruСПбГБУЗ «Городской клинический онкологический диспансер»РоссияCity Clinical Oncology CentreRussian FederationСПбГБУЗ «Городской клинический онкологический диспансер»; ФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова» Минздрава РоссииРоссияCity Clinical Oncology Centre; First Saint Petersburg State Medical University n. a. I. P. PavlovRussian Federation201714082017225Диагностика и онкотерапия1216Copyright © Манихас А.Г., Раевская Н.А., Манихас Г.М., 20172017Манихас А.Г., Раевская Н.А., Манихас Г.М.Manikhas A.G., Manikhas G.M., Raevskaya N.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/266

В статье представлены клинические случаи успешного применения химиотерапии эрибулином у пациенток с диссеминированным люминальным и тройным отрицательным раком молочной железы.

The article presents clinical cases of successful use of chemotherapy with eribulin in patients with disseminated luminal and triple negative breast cancer.

рак молочной железыхимиотерапияэрибулинbreast cancerchemotherapyeribulinReferencesЗлокачественные новообразования в России в 2015 году (заболеваемость и смертность) / под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М., 2017.Злокачественные новообразования в России в 2015 году (заболеваемость и смертность) / под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М., 2017.Rakha E.A., El-Sayed M.E., Green A.R. et al. Prognostic markers in triplenegative breast cancer. Cancer 2007; 109: 25-32.Rakha E.A., El-Sayed M.E., Green A.R. et al. Prognostic markers in triplenegative breast cancer. Cancer 2007; 109: 25-32.Haffty B.G., Yang Q., Reiss M. et al. Locoregional Relapse and Distant Metastasis in Conservatively Managed Triple Negative Early-Stage. Breast Cancer. J Clin Oncol 2006; 24 (36): 5652-7.Haffty B.G., Yang Q., Reiss M. et al. Locoregional Relapse and Distant Metastasis in Conservatively Managed Triple Negative Early-Stage. Breast Cancer. J Clin Oncol 2006; 24 (36): 5652-7.Ellis L.M., Bernstein D.S., Voest E.E. et al. American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes // J. Clin. Oncol. 2014. Vol. 32. № 12. P. 1277-1280.Ellis L.M., Bernstein D.S., Voest E.E. et al. American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes // J. Clin. Oncol. 2014. Vol. 32. № 12. P. 1277-1280.Cardoso F., Costa A., Senkus E. et al. ESO-ESMO 3nd international consensus guidelines for advanced breast cancer (ABC3). The Breast, 2017, 31: 244-259Cardoso F., Costa A., Senkus E. et al. ESO-ESMO 3nd international consensus guidelines for advanced breast cancer (ABC3). The Breast, 2017, 31: 244-259Инструкция по медицинскому применению препарата Халавен® (РУ ЛП-001782 от 28.07.2012, с изменениями от 08.02.2017).Инструкция по медицинскому применению препарата Халавен® (РУ ЛП-001782 от 28.07.2012, с изменениями от 08.02.2017).Towle M.J., Salvato K.A., Wels B.F. et al. Eribulin induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions // Cancer Res. 2011. Vol. 71. № 2. P. 496-505.Towle M.J., Salvato K.A., Wels B.F. et al. Eribulin induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions // Cancer Res. 2011. Vol. 71. № 2. P. 496-505.Funahashi Y., Okamoto K., Adachi Y. et al. Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models // Cancer Sci. 2014. Vol. 105. № 10. P. 1334-1342.Funahashi Y., Okamoto K., Adachi Y. et al. Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models // Cancer Sci. 2014. Vol. 105. № 10. P. 1334-1342.Ueda S., Saeki T., Takeuchi H. et al. In vivo imaging of eribulin-induced reoxygenation in advanced breast cancer patients a comparison to bevacizumab // Br. J. Cancer. 2016.Ueda S., Saeki T., Takeuchi H. et al. In vivo imaging of eribulin-induced reoxygenation in advanced breast cancer patients a comparison to bevacizumab // Br. J. Cancer. 2016.Yoshida T., Ozawa Y., Kimura T., et al. Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states. Br J Cancer 2014; 110: 1497-505.Yoshida T., Ozawa Y., Kimura T., et al. Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states. Br J Cancer 2014; 110: 1497-505.Cortes J., O'Shaughnessy J., Loesch D. et al. Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a Phase 3 open-label randomised study. Lancet 2011; 377(9769): 914-923.Cortes J., O'Shaughnessy J., Loesch D. et al. Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a Phase 3 open-label randomised study. Lancet 2011; 377(9769): 914-923.Blum J.L., Twelves C.J., Dutcus C., et al. Impact of the number of prior chemotherapy regimens on overall survival (OS) among subjects with locally recurrent or MBC treated with eribulin mesylate: results from the Phase III EMBRACE study. Presented at the 33rd Annual San Antonio Breast Cancer Symposium (SABCS), December 8-12, 2010; San Antonio, TX. USA. P. 6-13-01.Blum J.L., Twelves C.J., Dutcus C., et al. Impact of the number of prior chemotherapy regimens on overall survival (OS) among subjects with locally recurrent or MBC treated with eribulin mesylate: results from the Phase III EMBRACE study. Presented at the 33rd Annual San Antonio Breast Cancer Symposium (SABCS), December 8-12, 2010; San Antonio, TX. USA. P. 6-13-01.Kaufman P.A., Cortes J., Awada A. et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and taxan. J Clin Oncol. 2015; 33 (6): 594-601.Kaufman P.A., Cortes J., Awada A. et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and taxan. J Clin Oncol. 2015; 33 (6): 594-601.Pivot X., Marmé F., Koenigsberg R., Guo M., Berrak E., Wolfer A. Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy. Annals of Oncology. 2016; 27: 1525-31.Pivot X., Marmé F., Koenigsberg R., Guo M., Berrak E., Wolfer A. Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy. Annals of Oncology. 2016; 27: 1525-31.

The authors declare that there are no conflicts of interest present.